Últimas noticias sobre enGene Holdings (NASDAQ:ENGN) Bolsa

iShares Industrial Bond ETF

enGene Holdings

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

enGene Holdings Inc

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 34.21 percent decrease over losses of $(0.38) per share from the same period last year.

Earnings

Earnings Misses

News

ENGN

enGene Holdings Q2 EPS $(0.51) Misses $(0.49) Estimate

JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform and maintains $18 price target.

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on enGene Holdings, Maintains $18 Price Target

Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Overweight and lowers the price target from $37 to $34.

Morgan Stanley Maintains Overweight on enGene Holdings, Lowers Price Target to $34

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy and maintains $25 price target.

HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 4.35 percent decrease over losses of $(0.46) per share from the same period last year.

enGene Holdings Q1 2025 GAAP EPS $(0.48) Misses $(0.39) Estimate

WIIM

EnGene Holdings shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $26.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst John Mackay initiated coverage on Venture Global Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy rating and announced a price target of $29. Venture Global shares closed at $15.96 on Friday. <a href="https://www.benzinga.com/quote/VG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Allison Bratzel initiated coverage on enGene Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with an Overweight rating and announced a price target of $26. enGene shares closed at $5.90 on Friday. <a href="https://www.benzinga.com/quote/ENGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) with an Outperform rating and announced a price target of $16. aTyr Pharma shares closed at $3.41 on Friday. <a href="https://www.benzinga.com/quote/ATYR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiates coverage on Estrella Immunopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) with a Buy rating and announced a price target of $16. Estrella Immunopharma shares closed at $1.2350 on Friday. <a href="https://www.benzinga.com/quote/ESLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Steve Fleishman initiated coverage on Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Peer Perform rating. Shoals Technologies shares closed at $3.96 on Friday. <a href="https://www.benzinga.com/quote/SHLS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ATYR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="617" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18090836/image-155-1024x617.png" alt="" class="wp-image-786960" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18090836/image-155-1024x617.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18090836/image-155-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18090836/image-155-768x463.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/18090836/image-155.png 1063w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43730195/top-3-defensive-stocks-that-may-collapse-in-q1">Top 3 Defensive Stocks That May Collapse In Q1</a></li>
</ul>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ATYR

ESLA

SHLS

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Piper Sandler analyst Allison Bratzel initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Overweight rating and announces Price Target of $26.

Piper Sandler Initiates Coverage On enGene Holdings with Overweight Rating, Announces Price Target of $26

UBS analyst Colin Bristow downgrades enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) from Buy to Neutral and lowers the price target from $34 to $7.

Downgrades

UBS Downgrades enGene Holdings to Neutral, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

Offerings

Engene Holdings Said Entered Into Open Market Sale Agreement, May Offer & Sell Common Shares Of Up To $100M

enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.38) by 5.8 percent. This is a 99.03 percent increase over losses of $(151.22) per share from the same period last year.

enGene Holdings FY EPS $(1.46) Misses $(1.38) Estimate

Raymond James analyst Sean McCutcheon initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Outperform rating and announces Price Target of $23.

Raymond James Initiates Coverage On enGene Holdings with Outperform Rating, Announces Price Target of $23

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcac1f558000155e857/atif-malik">Citigroup analyst Atif Malik</a> initiated coverage on Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy rating and announced a price target of $120. Astera Labs shares closed at $86.45 on Friday. See how other analysts view this stock.</li>
<li>Jones Trading analyst Catherine Novack initiated coverage on Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy rating and announced a price target of $130. Korro Bio shares closed at $47.56 on Friday. See how other analysts view this stock.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59411d2985b07a0001615cae/ruplu-bhattacharya">B of A Securities analyst Ruplu Bhattacharya </a>initiated coverage on Ingram Micro Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announced a price target of $30. Ingram Micro shares closed at $22.75 on Friday. See how other analysts view this stock.</li>
<li>RBC Capital analyst Victoria McCulloch initiated coverage on TechnipFMC plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with an Outperform rating and announced a price target of $37. TechnipFMC shares closed at $28.18 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Silvan Tuerkcan initiated coverage on enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform rating and announced a price target of $18. enGene shares closed at $7.63 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FTI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="558" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-1024x558.png" alt="" class="wp-image-652827" style="width:664px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-1024x558.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18074942/image-181.png 1222w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

ALAB

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

JMP Securities analyst Silvan Tuerkcan initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform rating and announces Price Target of $18.

JMP Securities Initiates Coverage On enGene Holdings with Market Outperform Rating, Announces Price Target of $18

enGene Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) shares are trading higher by 7.2% to $9.54 during Friday&#8217;s session. The company announced it generated approximately $60 million in proceeds from a <a href="https://www.benzinga.com/pressreleases/24/10/b41542460/engene-announces-60-million-private-placement-financing">private placement</a>.
enGene announced a private placement to sell 6,758,311 common shares at $8.90 each, aiming to raise approximately $60 million before expenses. This financing is set to close on October 29, pending standard conditions, and involves participation from both new and existing investors, such as Deep Track Capital and Venrock Healthcare Capital Partners. 
The company says funds will support the development of enGene&#8217;s lead product, detalimogene voraplasmid, pre-commercial activities, potential expansion of the DDX platform, and general corporate needs.
Combined with existing cash, these proceeds are expected to sustain operations through 2027.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41544385/microstrategy-pushes-higher-as-blackrock-buys-in-but-peter-schiff-sees-a-crash-ahead">MicroStrategy Pushes Higher As BlackRock Buys In, But Peter Schiff Sees A Crash Ahead</a>
<h2 class="wp-block-heading">How To Buy ENGN Stock</h2>
By now you're likely curious about how to participate in the market for enGene Holdings &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of enGene Holdings, which is trading at $9.75 as of publishing time, $100 would buy you 10.26 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ENGN has a 52-week high of $43.00 and a 52-week low of $4.42.

Why enGene Holdings Stock Is Trading Higher

EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.

enGene Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90. The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any offering-related expenses.
The financing included participation from new and existing investors, including Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital and Venrock Healthcare Capital Partners.

enGene Announces That It Has Agreed To Sell 6,758,311 Of Its Common Shares At A Price Per Share Of $8.90; Anticipates The Gross Proceeds From The Private Placement To Be ~$60M

Comments

enGene Holdings

Noticias

Últimas noticias sobre enGene Holdings (NASDAQ:ENGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL